Metabolomics in pancreatic cancer biomarkers research

Pancreatic cancer is one of the worst prognoses of all malignancies. More than 40,000 deaths a year from this disease are observed in European Union alone. The only possibly curative treatment of pancreatic cancer is surgery, yet only 15–20% of patients have operable disease and even patients, which...

Full description

Saved in:
Bibliographic Details
Published in:Medical Oncology 2016-12, Vol.33 (12), p.133-133, Article 133
Main Authors: Tumas, Jaroslav, Kvederaviciute, Kotryna, Petrulionis, Marius, Kurlinkus, Benediktas, Rimkus, Arnas, Sakalauskaite, Greta, Cicenas, Jonas, Sileikis, Audrius
Format: Article
Language:English
Subjects:
Animals
Biomarkers, Tumor - metabolism
Hematology
Humans
Internal Medicine
Medicine
Medicine & Public Health
Metabolomics - methods
Oncology
Pancreatic cancer
Pancreatic Neoplasms - metabolism
Pathology
Review Article
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c508t-8bc3d97c640b2c59ef8b158187a7b81bc9feb28ccb350be3eb95968d607845973
cites cdi_FETCH-LOGICAL-c508t-8bc3d97c640b2c59ef8b158187a7b81bc9feb28ccb350be3eb95968d607845973
container_end_page 133
container_issue 12
container_start_page 133
container_title Medical Oncology
container_volume 33
creator Tumas, Jaroslav
Kvederaviciute, Kotryna
Petrulionis, Marius
Kurlinkus, Benediktas
Rimkus, Arnas
Sakalauskaite, Greta
Cicenas, Jonas
Sileikis, Audrius
description Pancreatic cancer is one of the worst prognoses of all malignancies. More than 40,000 deaths a year from this disease are observed in European Union alone. The only possibly curative treatment of pancreatic cancer is surgery, yet only 15–20% of patients have operable disease and even patients, which go through surgery and adjuvant chemotherapy, survival is less than 30%. The sensitive and specific biomarkers which could be used for the advance of early diagnostics are needed and constantly researched. Metabolomics is a technology which analyzes the concentrations of low-molecular-weight metabolites (the metabolome) has lately effectively developed due to the improvements in analytical technology. Metabolome analysis can be a one of the useful approaches for the biomarker discovery and disease diagnosis. Here we discuss recent discoveries in the field of pancreatic cancer metabolomics as well as the most promising biomarkers for diagnostics, prognosis and prediction.
doi_str_mv 10.1007/s12032-016-0853-6
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1836732020</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1836732020</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-8bc3d97c640b2c59ef8b158187a7b81bc9feb28ccb350be3eb95968d607845973</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMotlZ_gBdZ8OJldZI0X0cpfkHFi4K3sElndet-1GT34L83ZVVE8JSBPPPOzEPIMYVzCqAuImXAWQ5U5qAFz-UOmVIhTE45fd5NNRcqByFhQg5iXAMwKpjZJxOmNCjF2JSIe-wL19VdU_mYVW22KVofsOgrn_lUYshc1TVFeMMQs4ARi-BfD8leWdQRj77eGXm6vnpc3ObLh5u7xeUy9wJ0n2vn-cooL-fgmBcGS-2o0FSrQjlNnTclOqa9d1yAQ47OCCP1SoLSc2EUn5GzMXcTuvcBY2-bKnqs66LFboiWai4VZ5A0zMjpH3TdDaFN220pIU26nCWKjpQPXYwBS7sJVbruw1KwW6d2dGqTU7t1amXqOflKHlyDq5-Ob4kJYCMQ01f7guHX6H9TPwGK7IAD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835695292</pqid></control><display><type>article</type><title>Metabolomics in pancreatic cancer biomarkers research</title><source>Springer Nature</source><creator>Tumas, Jaroslav ; Kvederaviciute, Kotryna ; Petrulionis, Marius ; Kurlinkus, Benediktas ; Rimkus, Arnas ; Sakalauskaite, Greta ; Cicenas, Jonas ; Sileikis, Audrius</creator><creatorcontrib>Tumas, Jaroslav ; Kvederaviciute, Kotryna ; Petrulionis, Marius ; Kurlinkus, Benediktas ; Rimkus, Arnas ; Sakalauskaite, Greta ; Cicenas, Jonas ; Sileikis, Audrius</creatorcontrib><description>Pancreatic cancer is one of the worst prognoses of all malignancies. More than 40,000 deaths a year from this disease are observed in European Union alone. The only possibly curative treatment of pancreatic cancer is surgery, yet only 15–20% of patients have operable disease and even patients, which go through surgery and adjuvant chemotherapy, survival is less than 30%. The sensitive and specific biomarkers which could be used for the advance of early diagnostics are needed and constantly researched. Metabolomics is a technology which analyzes the concentrations of low-molecular-weight metabolites (the metabolome) has lately effectively developed due to the improvements in analytical technology. Metabolome analysis can be a one of the useful approaches for the biomarker discovery and disease diagnosis. Here we discuss recent discoveries in the field of pancreatic cancer metabolomics as well as the most promising biomarkers for diagnostics, prognosis and prediction.</description><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1007/s12032-016-0853-6</identifier><identifier>PMID: 27807722</identifier><identifier>CODEN: MONCEZ</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Animals ; Biomarkers, Tumor - metabolism ; Hematology ; Humans ; Internal Medicine ; Medicine ; Medicine &amp; Public Health ; Metabolomics - methods ; Oncology ; Pancreatic cancer ; Pancreatic Neoplasms - metabolism ; Pathology ; Review Article</subject><ispartof>Medical Oncology, 2016-12, Vol.33 (12), p.133-133, Article 133</ispartof><rights>Springer Science+Business Media New York 2016</rights><rights>Medical Oncology is a copyright of Springer, 2016.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-8bc3d97c640b2c59ef8b158187a7b81bc9feb28ccb350be3eb95968d607845973</citedby><cites>FETCH-LOGICAL-c508t-8bc3d97c640b2c59ef8b158187a7b81bc9feb28ccb350be3eb95968d607845973</cites><orcidid>0000-0002-9365-1843</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>313,314,780,784,792,27922,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27807722$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tumas, Jaroslav</creatorcontrib><creatorcontrib>Kvederaviciute, Kotryna</creatorcontrib><creatorcontrib>Petrulionis, Marius</creatorcontrib><creatorcontrib>Kurlinkus, Benediktas</creatorcontrib><creatorcontrib>Rimkus, Arnas</creatorcontrib><creatorcontrib>Sakalauskaite, Greta</creatorcontrib><creatorcontrib>Cicenas, Jonas</creatorcontrib><creatorcontrib>Sileikis, Audrius</creatorcontrib><title>Metabolomics in pancreatic cancer biomarkers research</title><title>Medical Oncology</title><addtitle>Med Oncol</addtitle><addtitle>Med Oncol</addtitle><description>Pancreatic cancer is one of the worst prognoses of all malignancies. More than 40,000 deaths a year from this disease are observed in European Union alone. The only possibly curative treatment of pancreatic cancer is surgery, yet only 15–20% of patients have operable disease and even patients, which go through surgery and adjuvant chemotherapy, survival is less than 30%. The sensitive and specific biomarkers which could be used for the advance of early diagnostics are needed and constantly researched. Metabolomics is a technology which analyzes the concentrations of low-molecular-weight metabolites (the metabolome) has lately effectively developed due to the improvements in analytical technology. Metabolome analysis can be a one of the useful approaches for the biomarker discovery and disease diagnosis. Here we discuss recent discoveries in the field of pancreatic cancer metabolomics as well as the most promising biomarkers for diagnostics, prognosis and prediction.</description><subject>Animals</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Metabolomics - methods</subject><subject>Oncology</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms - metabolism</subject><subject>Pathology</subject><subject>Review Article</subject><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp1kE1LAzEQhoMotlZ_gBdZ8OJldZI0X0cpfkHFi4K3sElndet-1GT34L83ZVVE8JSBPPPOzEPIMYVzCqAuImXAWQ5U5qAFz-UOmVIhTE45fd5NNRcqByFhQg5iXAMwKpjZJxOmNCjF2JSIe-wL19VdU_mYVW22KVofsOgrn_lUYshc1TVFeMMQs4ARi-BfD8leWdQRj77eGXm6vnpc3ObLh5u7xeUy9wJ0n2vn-cooL-fgmBcGS-2o0FSrQjlNnTclOqa9d1yAQ47OCCP1SoLSc2EUn5GzMXcTuvcBY2-bKnqs66LFboiWai4VZ5A0zMjpH3TdDaFN220pIU26nCWKjpQPXYwBS7sJVbruw1KwW6d2dGqTU7t1amXqOflKHlyDq5-Ob4kJYCMQ01f7guHX6H9TPwGK7IAD</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Tumas, Jaroslav</creator><creator>Kvederaviciute, Kotryna</creator><creator>Petrulionis, Marius</creator><creator>Kurlinkus, Benediktas</creator><creator>Rimkus, Arnas</creator><creator>Sakalauskaite, Greta</creator><creator>Cicenas, Jonas</creator><creator>Sileikis, Audrius</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9365-1843</orcidid></search><sort><creationdate>20161201</creationdate><title>Metabolomics in pancreatic cancer biomarkers research</title><author>Tumas, Jaroslav ; Kvederaviciute, Kotryna ; Petrulionis, Marius ; Kurlinkus, Benediktas ; Rimkus, Arnas ; Sakalauskaite, Greta ; Cicenas, Jonas ; Sileikis, Audrius</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-8bc3d97c640b2c59ef8b158187a7b81bc9feb28ccb350be3eb95968d607845973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Metabolomics - methods</topic><topic>Oncology</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms - metabolism</topic><topic>Pathology</topic><topic>Review Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tumas, Jaroslav</creatorcontrib><creatorcontrib>Kvederaviciute, Kotryna</creatorcontrib><creatorcontrib>Petrulionis, Marius</creatorcontrib><creatorcontrib>Kurlinkus, Benediktas</creatorcontrib><creatorcontrib>Rimkus, Arnas</creatorcontrib><creatorcontrib>Sakalauskaite, Greta</creatorcontrib><creatorcontrib>Cicenas, Jonas</creatorcontrib><creatorcontrib>Sileikis, Audrius</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest - Health &amp; Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Medical Oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tumas, Jaroslav</au><au>Kvederaviciute, Kotryna</au><au>Petrulionis, Marius</au><au>Kurlinkus, Benediktas</au><au>Rimkus, Arnas</au><au>Sakalauskaite, Greta</au><au>Cicenas, Jonas</au><au>Sileikis, Audrius</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metabolomics in pancreatic cancer biomarkers research</atitle><jtitle>Medical Oncology</jtitle><stitle>Med Oncol</stitle><addtitle>Med Oncol</addtitle><date>2016-12-01</date><risdate>2016</risdate><volume>33</volume><issue>12</issue><spage>133</spage><epage>133</epage><pages>133-133</pages><artnum>133</artnum><issn>1357-0560</issn><eissn>1559-131X</eissn><coden>MONCEZ</coden><abstract>Pancreatic cancer is one of the worst prognoses of all malignancies. More than 40,000 deaths a year from this disease are observed in European Union alone. The only possibly curative treatment of pancreatic cancer is surgery, yet only 15–20% of patients have operable disease and even patients, which go through surgery and adjuvant chemotherapy, survival is less than 30%. The sensitive and specific biomarkers which could be used for the advance of early diagnostics are needed and constantly researched. Metabolomics is a technology which analyzes the concentrations of low-molecular-weight metabolites (the metabolome) has lately effectively developed due to the improvements in analytical technology. Metabolome analysis can be a one of the useful approaches for the biomarker discovery and disease diagnosis. Here we discuss recent discoveries in the field of pancreatic cancer metabolomics as well as the most promising biomarkers for diagnostics, prognosis and prediction.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>27807722</pmid><doi>10.1007/s12032-016-0853-6</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-9365-1843</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1357-0560
ispartof Medical Oncology, 2016-12, Vol.33 (12), p.133-133, Article 133
issn 1357-0560
1559-131X
language eng
recordid cdi_proquest_miscellaneous_1836732020
source Springer Nature
subjects Animals
Biomarkers, Tumor - metabolism
Hematology
Humans
Internal Medicine
Medicine
Medicine & Public Health
Metabolomics - methods
Oncology
Pancreatic cancer
Pancreatic Neoplasms - metabolism
Pathology
Review Article
title Metabolomics in pancreatic cancer biomarkers research
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T16%3A59%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metabolomics%20in%20pancreatic%20cancer%20biomarkers%20research&rft.jtitle=Medical%20Oncology&rft.au=Tumas,%20Jaroslav&rft.date=2016-12-01&rft.volume=33&rft.issue=12&rft.spage=133&rft.epage=133&rft.pages=133-133&rft.artnum=133&rft.issn=1357-0560&rft.eissn=1559-131X&rft.coden=MONCEZ&rft_id=info:doi/10.1007/s12032-016-0853-6&rft_dat=%3Cproquest_cross%3E1836732020%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c508t-8bc3d97c640b2c59ef8b158187a7b81bc9feb28ccb350be3eb95968d607845973%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1835695292&rft_id=info:pmid/27807722&rfr_iscdi=true